Our Services
1
Research
Screening and research the market for potentially interesting projects and companies
2
Preselection
Preselecting projects and companies that are important for the SCI community and have a high chance to be successful and/ or gamechanger
3
Company Check
Company Due Diligence including possible patents, registration etc for companies in the medical field
4
Network Access
SCInvest offers privileged access to various outstanding hospitals, rehab centers and other important instiotutions in Europe and the world
5
Business Development
With many years of experience in business development, strategy, marketing and sales we help the companies to make their business a success.
6
Ambassador
We are also open to become ambassors of the companies we work together. If possible we will also co-invest.
-
We become ambassadors for the SCI company
-
We invest our time & money in selected companies
-
We have privileged access to various outstanding hospitals and rehab centers in Europe and the world
NeuroBioMat
A deeptech Company developing an innovative biomaterial to cure chronic spinal cord injuries
NeuroBioMat is currently fundraising money with SCInvest GmbH and looking for strategic partners to conduct an in-human clinical trial to establish the safety and efficacy of the device and developing a cost-effective therapy to maximise the functional recovery following Spinal Cord Injury.
NBM is looking for 2 mio Euro for making the first human / clinical trial starting at beginning of 2025.
The SPINEREP technology, developed by NeuroBioMat and produced by their partner, Polymer Expert in Bordeaux, adheres to the highest quality standards, positioning itself as a global leader. NeuroBioMat's extensive research across esteemed institutions in Europe and North America underscores SPINEREP's forefront status in regenerative medicine, targeting the restoration of motor, sensory, and autonomic functions in spinal cord injury patients.
Pre-clinical trials on animals have yielded exceptionally positive results, showcasing SPINEREP's efficacy and safety profile, solidifying its status as a groundbreaking solution for spinal cord injuries. Offering viscoelasticity, deformability, and a 90% porosity facilitating cell migration, SPINEREP boasts immediate bioadhesion, 100% biocompatibility, and FDA recognition as a breakthrough device, further fortified by its patents and trademarks.
Compared to competitors, SPINEREP's advantage lies in its standard surgical application and non-degradable technology, ensuring longer-lasting effects combined with rehabilitation efforts. Moreover, its availability for chronic stage patients with complete lesions broadens its market reach, potentially yielding significant returns for investors. In this dynamic market, where competitors have garnered valuations surpassing $800 million, SPINEREP's unique properties and market positioning signify substantial investment potential.
Get further information
We are looking forward to send you further information or making a videoconference